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The current methods for targeted drug delivery utilize ligands that must out-compete endogenous 
ligands in order to bind to the active site facilitating the transport. To address this limitation, we present 
a non-competitive active transport strategy to overcome intestinal barriers in the form of tunable 
nanosystems (NS) for transferrin receptor (TfR) utilizing gambogic acid (GA), a xanthanoid, as its ligand. 
The NS made using GA conjugated poly(lactide-co-glycolide) (PLGA) have shown non-competitive 
affinity to TfR evaluated in cell/cell-free systems. The fluorescent PLGA-GA NS exhibited significant 
intestinal transport and altered distribution profile compared to PLGA NS in vivo. The PLGA-GA NS 
loaded with cyclosporine A (CsA), a model peptide, upon peroral dosing to rodents led to maximum 
plasma concentration of CsA at 6 h as opposed to 24 h with PLGA-NS with at least 2-fold higher levels in 
brain at 72 h. The proposed approach offers new prospects for peroral drug delivery and beyond.
Receptor-mediated drug delivery using functional polymer nanosystems (NS) has been explored over the years 
to enhance the therapeutic index of drugs1–5. The recent use of receptor-mediated uptake in the gastrointesti-
nal tract (GIT) presents an exciting opportunity for targeted and enhanced delivery of NS via vitamin B126,7, 
folate-receptor8,9, neonatal fc receptor10 and transferrin-receptor (TfR)11–13. Due to its high expression, TfR is 
one of the prominent receptors explored for transport of NS across GIT11,14 and blood-brain barriers15,16 (BBB). 
TfR, responsible for the transport of iron bound transferrin across the GIT, is expressed in varying intensity 
across the GIT with the highest density in small intestine in villous cells of the epithelium17. Although TfRs are 
believed to be mainly concentrated on the basal and lateral sides of the epithelial cells in the small intestine, there 
are reports suggesting their presence on the apical side17 and concentration in clathrin-coated pits along the free 
cell margins18.
The ligands currently in use for receptor-mediated drug delivery must out-compete endogenous ligands 
in order to bind to the active site facilitating the transport6,8,10–13,19. Here, we present a novel non-competitive 
active transport strategy to overcome intestinal barriers by targeting TfR with tunable NS utilizing gambogic acid 
(GA), a xanthanoid, known for its affinity to TfR, independent of transferrin binding20,21. We have coupled GA to 
polylactide-co-glycolide (PLGA), the most widely used polymer in drug delivery22, via ethylenediamine (EDA) 
linker. The degree of ligand substitution on the NS surface is critical for receptor-mediated delivery, and can be 
optimized by controlling the mixing ratios of ligand-functionalized polymer to non-functional polymer23,24. This 
approach, utilizing small molecule non-competitive ligand for active drug delivery, enables the development of 
carrier systems that have no equivalent in the world of competitive ligands.
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Results and Discussion
Synthesis and Characterization of GA-conjugated PLGA. The carboxy-terminal end group of PLGA 
was activated with 1-ethyl-3-(dimethylaminopropyl)carbodiimide (EDC) and connected to n-boc-ethylenedi-
amine via an amide bond, which was then de-protected to get PLGA-EDA with a free amine group. The amine 
functionality allowed for the formation of an amide-linkage to the carboxyl group of GA in the subsequent reac-
tion (Fig. 1a). The covalent bonding of GA to PLGA was confirmed by NMR spectroscopy. The mild reactions 
employed in the conjugation process yield high amounts of products while preserving the structural integrity of 
the polymer backbone, as was evident from the GPC and MALDI-MS data, as well as unaltered thermal proper-
ties, observed in DSC (supplementary Fig. S1a–c).
The use of the biocompatible EDA linker25 to bind GA to PLGA served the dual purpose of activating PLGA 
end groups and imparting a high level of hydrophilicity26 to the ligand-terminus of the polymer chains. The 
hydrophilic end of the polymer chain facilitates the surface expression of ligands on NS during preparation in an 
aqueous environment. PLGA-GA itself exhibited higher hydrophilicity than PLGA in water contact angle analysis 
(Fig. 1b, supplementary Fig. S1d). In addition to PLGA-GA, rhodamine conjugated fluorescent PLGA-Rh was 
prepared by coupling rhodamine-NHS to PLGA-EDA.
Preparation and Characterization of PLGA-GA NS. To evaluate the avidity of GA activated NS 
towards TfR, four variations of NS were engineered by blending PLGA-GA and PLGA in varying quantities: 
PLGA(100%); PLGA-GA(20%)- PLGA(80%); PLGA-GA(60%)- PLGA(40%) and PLGA-GA(100%) (Fig. 1c)
(PLGA, PLGA-GA20, PLGA-GA60 and PLGA-GA100). PLGA-GA/PLGA blends in these concentrations yielded 
NS with 0, 4.04, 12.16 and 20.48 μ g GA/mg PLGA respectively. The NS stabilized using minimal amounts of 
didodecyldimethylammonium bromide (DMAB) surfactant exhibited a spherical morphology with a diameter of 
~110 nm (PDI ~0.1), which remained unchanged for all four variations of NS (Fig. 1d–e, supplementary Fig. S2a,b). 
Figure 1. Synthesis and Characterization of GA-conjugated PLGA and PLGA-GA NS. (a) Schematic 
illustration of synthesis of PLGA-GA and PLGA-Rh. (b) Water droplet contact angle on PLGA and 
PLGA-GA100 (c) Engineered PLGA-GA/PLGA NS. (d/e) SEM and DLS analyses of the size of PLGA-GA100 
NS. (f) Overlaid XPS survey spectra with an inset image of N 1 s scans of PLGA-GA/PLGA NS. (g) Overlaid 
UV/Vis absorption spectra of NS suspension with an inset image of the UV/Vis spectra of polymer solutions.
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Due to the interaction of the hydrophilic ligand-end of the polymer with the aqueous environment during the 
emulsification of organic phase carrying PLGA-GA, GA was expressed on the surface of the NS. An increasing 
trend of the amount of surface nitrogen in NS ranging from 0% to 100% PLGA-GA revealed by the x-ray photon 
spectra (XPS) indicated the surface expression of EDA, and hence the localization of GA on NS surface (Fig. 1f). 
It is ideal for the ligand to be expressed on the surface of the NS to provide access for the cell membrane receptors 
to bind to the ligands and internalize the NS. UV spectroscopy was also employed for surface characterization of 
PLGA-GA/PLGA NS following its established use to characterize adsorbed ligands on NS surface27,28 (Fig. 1g).
Incorporation of 4% (w/w) PLGA-Rh in the polymer mixture used to prepare NS yielded fluorescent NS 
(F-NS), fluorescing at excitation/emission (Ex/Em) wavelengths of 552/575 nm. The F-NS were employed in the 
cellular uptake, ex vivo intestinal tissue transport and in vivo distribution studies to track the NS.
In addition to non-fluorescent and fluorescent blank NS, cyclosporine A (CsA) loaded PLGA and 
PLGA-GA100 NS were prepared to evaluate CsA distribution kinetics in rodents. The NS prepared using the 
methods previously developed in our lab29 had the entrapment efficiency of 45% at 20% (w/w) loading or 90 μ g 
CsA/mg polymer, irrespective of the conjugation status of the polymer. The NS displayed a slightly increased size 
of 157 nm due to the incorporation of CsA in the polymer matrix. The PLGA-GA and their NS were stable in 
gastric and intestinal conditions for the transit periods (supplementary Fig. S3a–c).
ELISA Study to Evaluate Non-competitive Binding of PLGA-GA NS to TfR. GA has been pre-
viously shown to have affinity for TfR, independent of transferrin binding 20. To evaluate the translation of the 
avidity of GA for TfR in PLGA-GA NS, a sandwich ELISA method was employed. The initial study involved 
the determination of the effect of surface GA density of NS in their binding affinity to TfR. Fluorescent PLGA, 
PLGA-GA20, PLGA-GA60 and PLGA-GA100 NS (F-NS) were introduced to 200 ng of TfR (Fig. 2a). After incu-
bation and washing of the unbound NS, an increase in fluorescence intensity (FI) was seen with the increasing 
amount of PLGA-GA in the NS, and hence the surface density of GA. An increasing trend was observed in the 
height and area under the curves in wavelength scans for florescence excitation at 550-600nm as well as the FI 
values obtained at 578 nm, λ max for PLGA-Rh. (Fig. 2b–d). The total FI of the NS suspension available in the 
wells without TfR was also measured in order to ensure that the variation in the FI with TfR was caused by the 
binding of the NS to the receptor (supplementary Fig. S4a-d). The initial FI, which was similar for all NS suspen-
sions before the binding assay, was retained only by PLGA-GA100 at the end of the ELISA study, while the FI of 
others declined with the decrease in the amount of PLGA-GA in the NS. The similar FI for initial unwashed and 
final bound and washed PLGA-GA100 NS indicated that almost all the NS were bound to TfR. The colorimetric 
measurements for TfR levels depicted no significant reduction from the initial values signifying that GA does not 
compete with 2° antibody for TfR (Fig. 2e, supplementary Fig. S4e,f).
In the subsequent study, TfR was blocked using 7-peptide, a ligand with high affinity for TfR11 before treating 
with PLGA-GA/PLGA F-NS. Due to the lack of information available about the amount of 7-peptide required 
to completely block TfR, 250 ng of TfR was treated with 25, 75 and 150 ng of 7-peptide followed by estimating 
TfR levels using 2° TfR antibody. The colorimetric assay suggested no significant difference between the different 
amounts of 7-peptide used (Fig. 2f). Based on the results of the aforementioned assay, the highest tested 150 ng 
dose of 7-peptide was selected to sufficiently block TfR to evaluate the binding of PLGA-GA/PLGA NS to TfR in 
the presence of 2° antibody (Fig. 2g). Similar to the previous experiment devoid of a second ligand, an increase 
in FI was observed with the increasing surface GA density from PLGA to PLGA-GA100 (Fig. 2h,i). The increase 
in the binding capacity of PLGA-GA NS as a function of the surface density of GA was observed in spite of the 
decreased free TfR levels due to 7-peptide, confirmed by the colorimetric scans of the subsequently added 2° 
TfR antibody (Fig. 2j). Thus, it can be concluded that the ability of GA to bind non-competitively to TfR is pre-
served in the functionalized PLGA-GA NS. The DLS size distribution plots and SEM micrographs of PLGA or 
PLGA-GA100 NS at the dilutions used in the ELISA study are presented in supplementary Fig. S4g,h.
Transport Studies of PLGA-GA NS with/without Blocking of TfR and Toxicity Evaluation in 
Cultured Cells. Caco-2 (human colon adenocarcinoma cell line) cells are extensively used as in vitro intesti-
nal barrier model as they exhibit differentiated brush border on the apical surface with the expression of intestinal 
features like microvillus hydrolases, nutrient transporters and receptors including those for transferrin30,31. The 
cellular uptake of PLGA-GA/PLGA NS followed a pattern similar to their binding affinity to TfR reflected in the 
ELISA study. It was observed that suspending the NS directly in media or PBS caused excessive agglomeration 
(supplementary Fig. S5), thus limiting the uptake by cells. To avoid aggregation, NS (250 μ g or 500 μ g) were sus-
pended in water (200 μ l) and added to the culture wells followed by media after 5 min to allow the cells to bind 
and internalize the freely suspended NS followed by incubation for 1 h. Fluorescence microscopic investigation of 
the cell monolayers treated with PLGA-GA/PLGA F-NS revealed an increase in the amount of cellular uptake of 
the NS with the increase in the surface expression of GA (Fig. 3a).
This finding was further substantiated by the increase in FI for rhodamine in the monolayers treated with NS 
with increasing amount of PLGA-GA in the NS (Fig. 3b,c). A rightward shift in the cell population plots with 
respect to control was observed in Fluorescence activated cell sorting/scanning (FACS) corresponding to the 
increasing amount of rhodamine positive (Rh + ) cells (Fig. 3c). The shift in cell population increased with the 
increase in the amount of PLGA-GA present in the NS, concurrent with the FI and F-NS distribution observed 
in the microscopic evaluation. In addition, a separate new intense population of Rh + cells could be seen in the 
FACS plots indicative of some cells taking up more NS than others. This intense population of Rh + cells was more 
pronounced for the monolayers treated with 500 μ g NS. In general, the cellular uptake of NS was higher when 
treated with larger amount of NS. The images and FACS analysis for the cells treated with 250 μ g NS are presented 
in supplementary Fig. S6.
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To study the non-competitive affinity of PLGA-GA/PLGA NS to TfR in the presence of another ligand, the cells 
were pre-treated with anti TfR 1o antibody followed by treatment with 500 μ g of PLGA-GA/PLGA or PLGA F-NS. 
TfR blocking did not compromise the cellular uptake of any of the NS variations, confirming the non-competitive 
binding of GA to TfR (Fig. 3d,e). In another experiment, the cells were pre-treated with 10, 20 and 30 μ M GA 
to saturate the GA site on the receptor. In this case, a significant reduction in the uptake of PLGA-GA60 and 
PLGA-GA100 NS was observed but not for PLGA and PLGA-GA20 NS which rely on the passive uptake mech-
anisms. These findings substantiate our claim that the PLGA-GA NS employ TfR, non-competitively for their 
internalization into cells (Fig. 3f-k, supplementary Fig. S7). The PLGA/PLGA-GA NS localization was further 
confirmed by confocal images (Fig. 3l).
Figure 2. ELISA Study to Evaluate Non-competitive Binding of PLGA-GA NS to TfR. (a) Illustration of 
ELISA protocol used in the study. (b) Fluorescence excitation spectra of NS-receptor binding as a function of 
GA density. (c) Enlarged image of the boxed area in b. (d) Fluorescence intensity at 578 nm. (e) TfR levels after 
the binding of the 2° antibody. (f) TfR levels after binding of different amounts of 7-peptide to TfR. (g) Illustration 
of ELISA protocol used for competitive binding assay. (h) Fluorescence excitation spectra of NS-receptor binding 
as a function GA density in the presence 7-peptide. (i) Fluorescence intensity at 578 nm in the presence of 
7-peptide. (j) TfR levels in competitive binding assay.
www.nature.com/scientificreports/
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Figure 3. Transport Studies of PLGA-GA NS with/without Blocking of TfR and Toxicity Evaluation 
in Cultured Cells. (a) Cellular uptake of PLGA-GA/PLGA NS (treated with 500 μ g/mL FL-NS) (red) 
with cytoskeleton and nuclei labeled with green and blue (DAPI) respectively and imaged using EVOS-FL 
microscope (60X, scale bar represents 50 μ m). (b/c) FACS plots and quantification of Rh + cells. (d/e) Uptake 
of PLGA-GA NS across caco-2 cells on blocking TfR. (f–h) Histograms (FACS data) of rhodamine positive 
cells treated with 250 μ g PLGA-GA/PLGA NS after pre-treatment with 10, 20 and 30 μ M GA. (i–k) Histograms 
(FACS data) of rhodamine positive cells treated with 500 μ g PLGA-GA/PLGA NS after pre-treatment with 
10, 20 and 30 μ M GA. (l) Confocal laser scanning microscopy images of caco-2 cells treated with PLGA and 
PLGA-GA NS (merged images, NS-red (rhodamine); nucleus-DAPI; actin (green); bar represents 5 μ m. Images 
were analyzed using Zen 2012 software, where a median filter was applied followed by orthogonal sectioning to 
obtain sections of the XZ (green line, top margin) and YZ planes (red line, right margin) through the stack.
www.nature.com/scientificreports/
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Concentration dependent toxicity in caco-2 cells. Since GA has been established as a potent 
anti-cancer agent32,33 with cytotoxic capabilities, it was imperative to evaluate the safety of PLGA-GA NS. While 
no cell death was observed in cells treated with 10 μ M molecular GA, significant cell death of 25% and 46% was 
observed in those treated with 20 and 30 μ M GA respectively (Fig. 4b–d). The cells treated with 250 μ g of all 
PLGA-GA/PLGA NS and 500 μ g of PLGA-100 and PLGA-GA20 did not show any significant cell death com-
pared to control while 11% and 25% cell death was observed in case of cells treated with 500 μ g PLGA-GA60 and 
PLGA-GA100 respectively (Fig. 4e–l). Cell death observed in the latter case could be attributed to the cumulative 
effect of high concentration of polymer and available GA. However, a moderate treatment of 250 μ g NS appears 
to be safe for the cells. The amount of GA present in all the NS in 250 and 500 μ g was much lower than the estab-
lished safe dose of 60 mg/kg described in the literature34.
Ex vivo Transport of PLGA-GA NS through Intestinal Barrier. While caco-2 monolayers provide 
ample information about the receptor-mediated cellular uptake and safety of PLGA-GA NS, they do not mimic 
tissue-level transport and binding. To study the transport of the F-NS through the intestinal barriers, an ex vivo 
intestinal model35 (Fig. 5a) was employed by using a tubular section of jejunum of Sprague-Dawley (SD) rat, 
which is one of the intestinal areas with high density of TfR17. The sac like structure infused with NS (250 μ g/ml) 
suspended in water was placed in media simulating physiological conditions for 2 h followed by washing and 
cryo-sectioning of the tissue for analysis (supplementary Fig. S8a). Concurrent with the observation in caco-2 
monolayers, a large influx of NS into the intestinal tissue was observed for PLGA-GA NS with increasing amount 
surface GA density with highest uptake for PLGA-GA100 (Fig. 5b,c; supplementary Fig. S8b). The transport of 
the NS across the intestinal wall was confirmed by their appearance in the surrounding media via DLS and SEM 
analyses (supplementary Fig. S8c,d). These findings establish a clear role of active transport mediated by GA, 
since very low amount of F-NS without GA were absorbed by passive means.
Kinetics of Fluorescent PLGA-GA NS. The in vivo kinetics of PLGA-GA or PLGA F-NS were studied 
following a 50 mg/kg (~16 mg/rat) peroral dose and evaluation of red blood cells (RBC), plasma, small intestine, 
liver, spleen, kidneys and brain tissues for rats sacrificed at 2, 12 and 24 h. A gradual increase in RBC associated 
PLGA NS levels was observed over 24 h while PLGA-GA NS showed an initial increase until 12 h followed by a 
decline. The RBC associated PLGA-GA NS levels were lower than PLGA NS at all time points. Both NS displayed 
a similar concentration trend during 24 h in plasma as RBC, however the concentration of PLGA-GA NS was 
about 2-fold higher than PLGA NS at 12 h but slightly lower at 24 h (Fig. 6a–c, supplementary Fig. S9a–b). This 
finding suggests that PLGA-GA NS have a preferential residence in plasma over association with RBC during 
circulation, which can be attributed to the hydrophilic nature of PLGA-GA NS.
The presence of PLGA-GA NS in SI was highest at 2 h followed by a gradual decrease at 12 h with almost neg-
ligible amount present in the intestinal tissue at 24 h, indicative of complete transport across the intestinal barrier 
in the given timeframe (Fig. 6d, supplementary Fig. S9c). The fast absorption of PLGA-GA NS can be attributed 
to TfR mediated active transport. In comparison, a considerable amount of PLGA NS remained unabsorbed as 
indicated by their persistent levels observed in the tissue sections at all time points. A similar trend was observed 
in spleen where PLGA NS prevailed in high amounts until 24 h while PLGA-GA NS had a higher splenic concen-
tration only at 2 h, but very low and decreasing concentrations at 12 and 24 h, indicating possible recirculation 
(supplementary Fig. S9d). In contrast, the concentration of PLGA-GA NS was highest in liver at 12 h with much 
lower concentrations at 2 and 24 h (supplementary Fig. S9e). The low levels of PLGA-GA NS in liver and spleen, 
the major organs of reticuloendothelial system (RES) responsible for clearance of foreign bodies including NS, 
reflect the recirculation of NS. Gustafson et al.36 cite examples in their review of nanomaterial phagocytosis, that 
a majority of NS reside within the RES organs for over 2 weeks after being cleared from circulation. While this 
effect was evident in the case of PLGA NS for the duration of the study, it was not observed for PLGA-GA NS. The 
recirculation of PLGA-GA NS was further affirmed by the appreciable levels of these NS in plasma at 24 h despite 
negligible concentration in small intestine, eliminating the possibility of transport of any residual unabsorbed 
NS from SI as in the case of PLGA NS. The hydrophilicity of PLGA-GA NS plays an integral part in their recir-
culation, as they can evade opsonization and hence accumulation in RES and phagocytosis by macrophages37–40. 
Renal clearance can also be ruled out for the NS considering their size which is larger than the renal filtration 
cut-off41 and their absence in glomerular areas in kidney sections (supplementary Fig. S9f).
TfR has been established as a resident receptor on the brain vasculature involved in the uptake and transport 
of transferrin and anti-TfR antibodies across the BBB42. TfR has been exploited as a potential target to deliver 
drugs43 and drug carrier systems15 across the BBB. In the present study, the PLGA-GA NS were able to penetrate 
the BBB as is evident by their accumulation in brain tissue in appreciable amount, with maximum concentration 
at 2 h followed by a statistically insignificant decline at 12 h and further decline at 24 h (supplementary Fig. S9g). 
In contrast, insignificant amount of PLGA NS was observed at 12 and 24 h. In comparison to PLGA NS, the con-
centration of PLGA-GA NS in brain accounted to about 7- and 4-folds at 2 and 12 h respectively.
Cyclosporine A (CsA) Kinetics. A drug kinetics study for encapsulated CsA was performed in SD rats 
following a single peroral dose of 15 mg/kg plain or encapsulated CsA in PLGA and PLGA-GA NS. Plasma con-
centration of CsA between 0–72 h revealed that a concentration maximum (Cmax) was reached at 12 h (maximum 
time taken, Tmax) for plain CsA and 24 h for PLGA NS, but much sooner at 6 h for PLGA-GA NS (Fig. 7a,d). This 
finding resonates with the results of the plasma concentration of F-NS with maximum FI at 24 and 12 h for PLGA 
and PLGA-GA NS respectively. The plasma concentration profiles, area under the curve (AUC0–72) and Cmax for 
CsA were the highest for PLGA-GA NS indicative of a larger amount of these NS being transported across the 
intestinal barrier compared to PLGA NS and plain CsA. The significant decrease in Tmax for PLGA-GA NS offers 
renewed hope for the PLGA delivery systems which otherwise are not suitable for drugs needing immediate 
www.nature.com/scientificreports/
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Figure 4. Concentration dependent toxicity in caco-2 cells. Contour plots of viable cells. (a) Control.  
(b–d) Increasing levels of cell death observed by increasing the amount of GA used to treat the cells with 10 μ M  
treatment showing negligible cell death. (e–h) Cells treated with 250 μ g PLGA-GA/PLGA NS with increasing 
amount of surface GA density showing negligible to very low cell death with no significant differences between 
groups. (i–l) Cells treated with 500 μ g PLGA-GA/PLGA NS with increasing amount of surface GA density 
showing more cell death compared to 250 μ g dose which may be due to the cumulative effect of excessive 
polymer and more GA available on the surface. The cell death was lower compared to the groups with 20 and 
30 μ M GA treated cells.
www.nature.com/scientificreports/
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release profiles or those with a narrow therapeutic index (e.g., CsA) where Cmax can be detrimental for efficacy 
while maintaining the AUC. The concentration of CsA in liver at the termination of study (72 h) was lower for 
PLGA-GA NS than PLGA NS but higher than plain CsA (Fig. 7b). On the other hand, brain had a 2-fold higher 
concentration of CsA in PLGA-GA NS group than PLGA NS, following the trend observed in vivo F-NS distribu-
tion study (Fig. 7c). PLGA and PLGA-GA NS show an opposing trend of CsA concentration in brain compared 
to plasma where CsA concentration is higher for PLGA NS than PLGA-GA NS. This finding is indicative of 
enhanced absorption of PLGA-GA NS in tissues without being restricted to RES or plasma. Thus, it can be con-
cluded that the PLGA-GA NS with encapsulated drug can effectively deliver the drug payload across the intestinal 
barrier and to target organs with high TfR density, like brain.
Figure 5. Ex vivo Transport of PLGA-GA NS through Intestinal Barrier. (a) Illustration of the experimental 
setup and mechanism of NS transport across intestinal tissue. (b) Representative fluorescence images of the  
ex vivo cryosections of jejunum obtained by CLSM (12× , scale bar represents 50 μ m). TfR was stained using 
anti-TfR antibody (green). (c) Mean fluorescence intensity (MFI) quantified in the intestinal sections.
www.nature.com/scientificreports/
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Figure 6. Kinetics of Fluorescent PLGA-GA NS. (a) Images of blood smears obtained using EVOS-FL 
microscope (60× , scale bar represents 50 μ m). (b) MFI quantified in the blood smears. (c) Plasma fluorescence 
plotted as ex/em (552/575) profiles. Representative images and quantified MFI of rhodamine (red) in tissue 
sections (20× , scale bar represents 50 μ m). Small intestine TfR is labelled green demonstrating the receptor 
presence on apical side.
www.nature.com/scientificreports/
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Conclusions
We have described the use of GA, an established anti-tumor agent with a high affinity for TfR, as a non-competitive 
targeting moiety for peroral delivery of PLGA based NS. PLGA-GA NS are safe with the amount of GA used as the 
targeting agent and are internalized by cells expressing TfR. Blank and drug loaded PLGA-GA NS have the ability 
to cross the intestinal barrier to reach and stay in circulation for a long time, in part due to recirculation from 
organs, owing to their high hydrophilicity. Due to active transport of these NS, they can decrease the time taken 
(Tmax) to achieve concentration maximum (Cmax) for orally delivered encapsulated drugs compared to untar-
geted PLGA NS. In addition, PLGA-GA NS have the ability to penetrate the BBB in appreciable quantities. Thus, 
PLGA-GA NS offer a novel platform for peroral delivery of drugs utilizing a small molecule, non-competitive 
ligand for active drug delivery, enabling the development of carrier systems that have no equivalent in the world 
of competitive ligands.
Methods
Materials. PLGA 50:50 (Resomer 503H, viscosity 0.32–0.44 dl/g and MW 24,000–38,000) was purchased 
from Evonik (Darmstadt, Germany), n-boc-ethylenediamine from Combi-Blocks (San Diego, USA) and gambo-
gic acid from Broadpharm (San Diego, USA). All other reagents, unless otherwise mentioned, were of analytical 
grade and were purchased from Fisher Scientific (USA).
Transferrin Receptor (TfR) ELISA assay kit was purchased from Eagle Biosciences (Nashua, USA). For 
cell culture experiments, caco-2 cells and Dulbecco’s Modified Eagle Medium (DMEM/F-12) were purchased 
from ATCC (Manassas, USA), human/mouse specific TfR primary antibody from Abcam (Cambridge, USA), 
ActinGreen and NucBlue molecular probes from Life technologies (Carlsbad, USA). All other reagents were cell 
Figure 7. Cyclosporine A (CsA) Kinetics. (a) Plasma concentration profile of CsA over 72 h period (Grey: 
Plain CsA; Solid Black: PLGA NS CsA; Dotted Black: PLGA-GA NS CsA). (b) Liver distribution of CsA at 
the end of the study (72 h). (c) Brain distribution of CsA at the end of the study (72 h). (d) Pharmacokinetics 
parameters.
www.nature.com/scientificreports/
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culture grade and were purchased from Fisher Scientific (USA). ProLong Gold antifade mountant with DAPI 
was purchased from Life Technologies (Carlsbad, USA). CsA ELISA kit specific for rat was purchased from 
MyBioSource [MBS263904] (San Diego, USA).
Synthesis of GA-conjugated PLGA. PLGA (500 mg; 0.0161 mmol) was stirred with 1-Ethyl-3-
(dimethylaminopropyl) carbodiimide (EDC) (15.43 mg; 0.0805 mmol) in 5 ml CH2Cl2 for 30 min. Subsequently, 
n-boc-ethyelenediamine (12.90 mg; 12.75 μ l; 0.0805 mmol) and N,N-Diisopropylethylamine (DIEA) (10.40 mg; 
4.02 μ l; 0.0805 mmol) were added and the reaction was continued under inert conditions for 18 h at room temper-
ature. The reaction mixture was precipitated in 100 ml cold diethyl ether to get a white polymer. The polymer was 
further purified by re-dissolving it in 5 ml methylene chloride (CH2Cl2) and precipitating in cold diethyl ether. 
The purified polymer was dried under vacuum to get 483 mg of dry powder. The dried polymer was reconstituted 
in 3.3 ml 10:1 CH2Cl2:TFA solution and stirred under inert conditions for 1 h. The solvent was evaporated on 
a rotary evaporator to get a clear viscous residue which was dissolved in 3 ml CH2Cl2 and precipitated in cold 
ether. The polymer thus obtained was dried under vacuum to get 431 mg (86% theoretical yield) of dry PLGA-EDA. 
1H NMR (500 MHz, CDCl3) δ ppm 1.54–1.62 (m, 3H), 2.80 (s, 2H), 3.78 (s, 2H), 4.69–4.90 (m, 2H), 5.15–5.31 (m, 1H).
To conjugate GA to PLGA-EDA, GA (25.84 mg; 0.0411 mmol) and EDC (9.46 mg; 0.043 mmol) were first 
dissolved in CH2Cl2 (1 ml) and stirred under inert conditions for 30 minutes. To the bright orange solution thus 
obtained, a solution of PLGA-EDA (424 mg; 0.0137 mmol) and DIEA (6.37 mg; 8.6 μ l; 0.0493 mmol) in CH2Cl2 
(2 ml) was added. The reaction mixture was further stirred for 18 h and then precipitated in 50 ml cold diethyl 
ether. The polymer was purified by dissolving in 3 ml CH2Cl2 and precipitating in cold diethyl ether. Finally, the 
polymer was washed with distilled water and dried under vacuum for 2 h to get 376 mg of yellow PLGA-GA 
(74% theoretical yield). 1H NMR (500 MHz, CDCl3) δ ppm 1.43–1.81 (m, 32H), 2.05 (m, 3H), 2.35 (m, 4H), 
3.45–3.53 (m, 4H), 4.58–4.98 (m, 2H), 5.46–5.48 (m, 2H), 5.46–5.48 (m, 2H), 5.13–5.31 (m, 1H), 6.70 (m, 1H), 
6.68 (m, 1H), 7.56–7.59 (m, 2H).
For the synthesis of PLGA-Rh, NHS-Rhodamine (1.7 mg; 0.0032 mmol), PLGA-EDA (50 mg; 0.0016 mmol) 
and DIEA (0.414 mg, 0.56 μ l; 0.0032 mmol) were dissolved in DMF (1 ml) and stirred in an amber vessel under 
inert conditions for 12 h. The reaction mixture was the poured into 15 ml distilled water to precipitate the poly-
mer. The polymer was further washed with distilled water twice to remove residual unreacted NHS-Rhodamine 
and dried under vacuum for 2 h to get 39 mg (76% theoretical yield) of pink colored PLGA-Rh.
Characterization of GA-conjugated PLGA. All conjugated polymers and their intermediates were char-
acterized for their chemical structure on a 500 MHz NMR. The molecular weights of the parent PLGA and conju-
gated PLGA-GA were evaluated using Agilent 1220 Infinity HPLC connected to Agilent 1260 Infinity refractive 
index detector (RID) to serve as a Gel Permeation Chromatography (GPC) system. The column used for the GPC 
analysis was Agilent PLgel 5μ m MIXED-D column. The column was calibrated against polystyrene standards, and 
chloroform was used as a dissolving medium and eluent for both calibration standards and experimental samples.
Addition of GA to PLGA was also assessed using VWR 6300PC Double beam spectrophotometer. In addition 
to pure polymers, PLGA-GA/PLGA solution blends with 20% and 60% of PLGA-GA in the total weight of the 
mixture were analyzed. The pure polymer and their mixtures were dissolved in ethyl acetate and their absorbance 
spectra were scanned in the UV and visible light regions in a quartz cuvette.
Thermal analysis of PLGA and PLGA-GA was performed on TA Q50 differential scanning calorimetry (DSC) 
in the heat/cool/heat mode, where the polymer samples were heated at 10 °C/min from 0–200 °C and cooled at 
5 °C/min in a covered aluminum pan under nitrogen environment.
In order to study the hydrophilicity of the aforementioned polymers and polymer mixtures, samples were 
prepared by coating glass coverslips with the polymers by solvent casting. 100 μ l of each polymer solution in ethyl 
acetate at a concentration of 50 mg/ml was evenly spread on the coverslip and allowed to air dry followed by dry-
ing under vacuum to evaporate residual solvent. The contact angle of water droplets on the polymer surface was 
measured using Dataphysics OCA15EC contact angle measuring system.
Preparation of PLGA-GA NS. Four 50 mg batches (n = 3) were prepared by mixing varying amounts 
of PLGA-GA and PLGA in the ratios that included PLGA (100%), PLGA (80%)-PLGA-GA (20%), PLGA 
(40%)-PLGA-GA (60%) and PLGA-GA (100%). To prepare the fluorescent NS, 4% (w/w) PLGA-Rh was added 
to the polymer mixtures.
The organic phase was prepared by dissolving 50 mg polymer in 2.5 ml ethyl acetate by stirring at 1000 rpm 
for 30 min. A 1% solution of N-dodecyl-N,N-dimethylammonium bromide (DMAB) in 5 ml distilled water was 
prepared by stirring at 1000 rpm for 20 min to serve as the aqueous phase. The organic phase was added dropwise 
to the aqueous phase while stirring at 1500 rpm to form an emulsion, which was further stirred at 1500 rpm for 
5 min followed by homogenization at 15,000 rpm for 7 min. The final emulsion was diluted with 20 ml distilled 
water and stirred at 1000 rpm for 3 h to allow the diffusion and evaporation of organic solvent. NS were recovered 
by centrifugation at 15000 × g at 4 °C for 30 min. The pellet was suspended in 1 ml water with 5% (w/v) trehalose 
dihydrate for cryoprotection. The NS were pre-frozen for 8 h at − 80 °C and freeze-dried under 0.004 mBar pres-
sure at − 50 °C for 24 h followed by secondary drying at 20 °C for 12 h.
For the preparation for CsA loaded NS, the drug (10 mg) was dissolved in the organic phase for 20% (w/w) loading 
with respect to the polymer. All other steps in the preparation remained the same except the replacement of homogeni-
zation with sonication at 20% amplitude for 30 sec and the concentration of DMAB used, in this case 0.25%.
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Characterization of PLGA-GA NS. Particle size of blank and drug loaded NS was detected using 
Brookhaven dynamic light scattering system (DLS). The sample was prepared by diluting a small amount of fresh 
NS suspension or freeze-dried sample in 3 ml distilled water.
The morphology and size of the NS was further evaluated using JEOL JSM-7500F ultra-high resolution field 
emission scanning electron microscope (FE-SEM). The samples for SEM were prepared by depositing 2 μ l suspen-
sion of freeze-dried NS on 20 mesh copper TEM grids with lacy carbon (Ted Pella Inc.) and subsequent drying. 
The lacy carbon on the copper grid provides a porous substrate for the nanoparticles to settle without forming 
an aggregate due to the surface tension of sugary water as on traditional plain SEM substrates. The samples were 
coated with 4 nm layer of platinum/palladium to introduce conductivity.
Fresh NS suspensions were also subjected to UV spectrophotometry for the evaluation of their surface chem-
istry. Similar to the polymer solutions, wavelength scans in UV and visible regions were performed for all the NS 
suspensions. The UV spectra of the NS displayed similar absorbance pattern to polymer blends in solution but 
were considerably broader due to scattering of light by the motion of NS in suspension.
The surface chemistry of the NS was further evaluated by X-ray photon spectrophotometry (XPS) using 
Omicron XPS system with magnesium ion source. Survey, C 1 s, O 1s, and N 1s scans of the NS surface were per-
formed on freeze-dried samples deposited on carbon tapes. The freeze-dried NS were smeared on approximately 
0.25 mm2 sections of carbon tape attached to the sample pucks for XPS and the extra powder was removed using 
an argon pressurized purge. Equal area of carbon tape used to prepare samples ensured that the same amount of 
NS powder was deposited in each case. Extra caution was observed with maintaining the dryness of samples as 
moisture absorbed by trehalose in the NS caused outgassing in the high vacuum environment, thus disrupting 
sample analysis by shutting off of the system due to vacuum loss. All the characterization protocols had been 
thoroughly optimized before the final measurements were obtained.
For drug entrapment, the pellets of the CsA loaded NS obtained after centrifugation were dissolved in 3 ml 
acetonitrile. The amount of drug entrapped in the NS was determined by HPLC with a diode array detector 
(DAD) (Agilent 1220 infinity), using ODS Hypersil (150 × 4.6 mm; 5 μ m) column at 70 °C with acetonitrile: 
Methanol: 0.05 M Phosphoric acid (45:40:15) as mobile phase eluting at 0.7 ml/min. The wavelength of the DAD 
was set to 210 nm with 360 nm reference wavelength and a window of ± 4 nm. The retention time of CsA was 
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ELISA study to evaluate the non-competitive binding of PLGA-GA NS to TfR. All variations of 
fluorescent and non-fluorescent PLGA-GA/PLGA NS were suspended in dH2O at the concentration of 250 μ g/ml. 
25 μ l of each NS suspension was added to the wells of 96-well ELISA plate. All experiments were performed 
in triplicates. At these concentrations, the amount of GA available on the NS in each 25 μ l sample amounts to 
0, 50, 150 and 250 ng/ml for PLGA, PLGA-GA20, PLGA-GA60 and PLGA-GA100 respectively. To study the 
binding affinity of PLGA-GA NS to TfR, 25 μ l of 200 ng/ml solution of TfR and 150 μ l of horseradish peroxi-
dase (HRP)-conjugated 2° antibody were added into each well containing samples. The samples were mixed 
for 10 min on a rocker. The reaction was allowed to proceed for another two hours without shaking at room 
temperature. ELISA plate was then inverted to empty the contents of the wells. At this point, the fluorescence in 
the wells with F-NS samples was measured using microplate reader at excitation/emission (Ex/Em) specific to 
F-NS (552/575 nm) to quantify the total F-NS available in each well. The wells were washed three times with the 
washing buffer provided in the ELISA kit and dried with paper towels. 200 μ l of substrate solution, also provided 
with the ELISA kit, was added to the wells and incubated in the dark at room temperature for 30 min. To quantify 
TfR, the absorbance optical density (OD) of each well was measured at 450 nm using a microplate reader with 
background correction wavelength of 570 nm. Fluorescence was also measured again for the F-NS sample wells 
to quantify bound NS.
In the second study, 7-peptide, a TfR specific ligand, was used in an attempt to block the active site of TfR to 
assess the non-competitive binding of PLGA-GA NS. A 25 μ l of 250 ng/ml solution of TfR with 2.5 μ l of 25, 75 or 
150 ng/ml of 7-peptide solution were added into the wells. 150 μ l of HRP-conjugated 2° antibody was then added 
into each well and the reaction was carried as described above and the OD was measured to quantify TfR levels.
Subsequently, blocking experiments were conducted following the similar protocol, where PLGA-GA or 
PLGA NS were introduced prior to the addition of 2° antibody. In this case, 25 μ l of F-NS suspension, 25 μ l of 
250 ng/ml solution of TfR, 2.5 μ l of 150 ng/ml solution of 7-peptide and 150 μ l of HRP-conjugated 2° antibody 
was added into the ELISA plate wells. All other procedures including reaction, washing and analysis remained the 
same as described for the first ELISA study.
Caco-2 cell culture. Caco-2 cells (passage 7) were seeded at a density of 4.0 × 105 cells/well in a 6-well plate 
for all experiments (n = 3) and cultured for 48 h in 2 ml Dulbecco’s Modified Eagle Medium (DMEM/F-12) con-
taining 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin solution (v/v) at 37 °C/5% CO2.
Tuning avidity of PLGA-GA NS to TfR in caco-2 cells. Freeze-dried F-NS were suspended in dH20 at a 
concentration of 250 and 500 μ g/ml. Caco-2 cells were incubated with the 200 μ l of F-NS suspension for 5 min at 
37 °C/5% CO2, followed by addition 1.8 ml serum free medium and further incubation for 1 h at 37 °C/5% CO2. 
The cells were washed three times with phosphate buffered saline (PBS, pH 7.4) and further processed for fluores-
cent microscopy and FACS as described below. No noticeable changes were observed in the cell morphology or 
size due to addition of 200 μ l of water (SI Figure 10). There were reports indicating that 25% hypotonic stimulus 
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caused either little or no swelling in caco-2 cells due to the lack of caveolin-1, a 21–24 kDa membrane protein that 
modulates the activity of the volume-regulated anion channels (VRACs)44–46. In this study, the volume of water 
used constitutes ~10% of total volume and the cells stayed in contact with water only for 5 min.
Uptake of PLGA-GA NS across caco-2 cells after blocking TfR. For blocking experiments, caco-2 
cells (n = 3) were incubated with 10 μ g/mL of human/mouse specific TfR primary antibody in 6-well plate for 
30 min at 37 °C in CO2 incubator. After three consecutive washings with PBS, F-NS were added and incubated for 
further 1 h. These were then washed with PBS 3 times and trypsinized and subjected to FACS analysis.
Uptake of PLGA-GA NS in caco-2 cells after pretreatment with GA. For the receptor blocking 
experiment, caco-2 cells (n = 3) were pre-incubated with 10, 20 and 30 μ M GA at 37 °C/5% CO2 for 15 min prior 
to the addition of F-NS. 5 mM GA stock solution was previously prepared in dimethyl sulfoxide (DMSO) and 2, 
4 and 6 μ l was added to cell culture medium to obtain 10, 20 and 30 μ M (6.29; 12.58; 18.86 μ g) final concentration 
respectively. After incubation with F-NS, the cells were washed three times with PBS and further processed for 
fluorescent microscopy and FACS as described below.
Concentration dependent toxicity in caco-2 cells. In order to study the effect of increasing concentra-
tion of GA on the viability of caco-2 cells (n = 3), they were incubated with 10, 20 and 30 μ M molecular GA for 
15 min at 37 °C/5% CO2 and washed with PBS. In addition, cells were treated with all variations PLGA-GA/PLGA 
NS in the concentration of 250 μ g (5 μ g GA) and 500 μ g (10 μ g GA)/ml for 1 h at 37 °C/5% CO2 and subsequently 
washed with PBS and further processed for FACS analysis as described below.
Fluorescent Microscopy. The cells were fixed by keeping them in 4% paraformaldehyde for 20 min at room 
temperature and subsequently washing three times with PBS. The fixed cells were stained for actin (green) and 
nuclei (blue) using ActinGreen and NucBlue molecular probes. The cells were imaged using EVOS-FL micro-
scope at 60× magnification.
Fluorescence activated cell sorting/scanning (FACS). The washed cells were dissociated using 0.25% 
trypsin/0.02% (Ethyelendiaminetetraacetic acid) EDTA solution to obtain a cell suspension which was centri-
fuged at 400 × g/4 °C for 5 min. The cells were re-suspended in 500 μ l PBS containing 1% (w/v) bovine serum 
albumin (BSA) and centrifuged at 400 × g/4 °C for 5 min. This washing step was repeated 3 times. The final cell 
suspension in PBS with BSA was subjected to FACS analysis using BD FACS Calibur instrument. FACS data was 
analyzed using Flow Jo 9.8.5 software.
Animals. Male SD rats (210–230 g) (Harlan, USA) colony was maintained in the animal quarterin accordance 
to the Texas A&M Institutional Animal Care and Use Committee (IACUC).
Animal Study Approval. All experimental protocols were reviewed and approved by the Texas A&M 
University IACUC. All animal procedures for this study were carried out in accordance with the relevant IACUC 
guidelines and approved protocols.
Ex vivo transport of PLGA-GA NS through intestinal barrier. Male SD rats (n = 3) (210–230 g) were 
euthanized by CO2 asphyxiation followed by cervical dislocation. The jejunum regions of the small intestine of SD 
rats were dissected, washed with ice cold PBS three times and cut into 2 inch long pieces. One end of each trun-
cated small intestine section was tied with a nylon thread and F-NS at the concentration of 250 μ g/ml in dH2O 
were pipetted into the open end. After adding F-NS, the open end was closed with fine forceps and tied with nylon 
thread. This bag-like structure was immersed in Hank’s Balanced Salt Solution (HBSS) with calcium and mag-
nesium, in a 30 mm petri dish and incubated at 37 °C/5% CO2, for 2 h with intermittent shaking at 15 min inter-
vals. After 2 h, small intestine section was removed from the dish, the ends were clipped and the open tube thus 
obtained was washed with the PBS three times to remove unbound F-NS. The small intestine tissue samples were 
embedded in Optimal Cutting Temperature (OCT) media for sectioning and cut into 4-μ m thick cross-sections 
with a cryostat (ThermoScientific, USA) at −20 °C. The tissue sections were further processed for confocal imag-
ing as described in later sections.
Kinetics of fluorescent PLGA-GA NS. Male SD rats (n = 3) were perorally dosed 50 mg/kg (~16 mg/rat) 
PLGA or PLGA-GA100 (~325 μ g GA) suspended in 1 ml water using an oral gavage needle. The rats were allowed 
to have access to standard chow and water for the duration of study. Animals were sacrificed at 2, 12 and 24 h by 
CO2 asphyxiation followed by cervical dislocation. Blood (~ 5 mL) was collected from the sacrificed animals via 
heart puncture. In addition, small intestine (jejunum ~ 5 cm), liver, spleen, kidneys, and brain were excised for 
confocal imaging described in the later section. Small intestines’ were flushed with saline several times at room 
temperature to remove unabsorbed NS and food particles.
Blood smears were prepared using fresh blood (2 μ l/coverslip) and imaged using EVOS-FL microscope at 60× 
magnification in differential interference contrast (DIC) and fluorescence imaging modes for particles and both 
were later merged to get final images. Fluorescence was quantified using image J software (NIH). Plasma was 
separated from blood by centrifugation at 1620 × g/4 °C for 20 min. Plasma fluorescence was observed in Infinite 
F200 microplate reader (Tecan) at Ex/Em specific for F-NS (552/575 nm) in samples diluted to 1:50 in PBS.
Confocal microscopy. Caco-2 cells. 50,000 Caco-2 cells/mL were cultured for 48 h at 37 °C and 5%CO2 
according to manufacturer’s protocol on 8 well 1 μ m-slide ibiTreat (ibidi, 82152 Martinsried, Germany) culture 
plate. Cellular uptake experiment was performed as previously mentioned for cell treatment with 3 μ g/ml F-NS. 
Images were acquired on CLSM at 40× original magnification. Images were processed using Zen 2012 software.
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:29501 | DOI: 10.1038/srep29501
Ex vivo intestinal sections. For imaging the cryosections of rat jejunum from the ex-vivo experiment, they were 
stained with primary mouse monoclonal anti-TfR-CD71 antibody diluted 1:200 in PBS containing 3% goat serum 
and incubated overnight at 4 °C. The sections were then washed with PBS and anti-mouse secondary antibody 
conjugated with Alexa Fluor 488 was added. The sections were further incubated at room temperature for 2 h and 
washed three times with PBS. Nuclei were stained with DAPI.
Tissue sections from in vivo fluorescent NS study. To image the tissue section from small intestine, liver, spleen, 
kidney and brain from rats from in vivo F-NS study were also embedded in OCT medium and 4 μ m cryosec-
tions were prepared using cryostat. All samples were stored at − 80 °C until further processing. DAPI (Prolong 
Gold antifade mountant with DAPI) was used to stain the nuclei in all tissue sections. Similar to the ex vivo 
study, the small intestine sections from the in vivo study were stained for TfR using primary and secondary 
antibodies.
Multiple optical sections of each tissue sample were imaged using a ZEISS LSM 780 confocal laser scanning 
microscope. Images captured during microscopy analysis of the tissue sections were analyzed using ZEN soft-
ware. Four images were captured for each animal in a group for each tissue (total of 12 images per group). Image 
J software (NIH) was used to measure and compare the fluorescence intensity of the tissue samples.
Cyclosporine A (CsA) kinetics. Plain CsA (15 mg/kg in carboxymethylcelluose), PLGA and PLGA-GA100 
NS (~41 mg for 15 mg/kg CsA based on 45% EE at 20% loading) suspended in 1 ml water were dosed perorally 
to the respective groups of rats (n = 4) using an oral gavage needle. Blood samples (100 μ l) were collected from 
rats through tail vein at 0.5, 1, 2, 6, 12, 24, 48 and 72 h and stored in BD microtainer tubes containing K2EDTA 
as anticoagulant and stored at 4 °C. Blood samples were centrifuged at 1620 × g/4 °C for 20 min to separate 
plasma which was then stored at −80 °C. CsA concentration in plasma was measured using CsA ELISA kit 
specific for rat. Plasma was diluted for the CsA analysis (8.5 times) with the diluent provided in the kit. All 
rats were sacrificed at 72 h by CO2 asphyxiation followed by cervical dislocation. Liver and brain tissues were 
homogenized in tissue lysis buffer and centrifuged at 20817 × g/4 °C for 30 min. Supernatant was collected 
and stored at − 80 °C. CsA ELISA kit was used to measure tissue level concentrations of CsA after appropriate 
dilution (5 times in this case) using the diluent provided by the manufacturer and converted in to the μ g/gram 
weight for each tissue.
Statistical analysis. All values are expressed as mean ± standard error of the mean (SEM), and p-values 
were assessed by one-way analysis of variance (ANOVA). For the kinetics study two-way ANOVA was used. A 
p < 0.05 was considered statistically significant. Comparison of more than two groups (PLGA and PLGA-GA NS 
and between the groups) was performed with Tukey’s multiple comparison tests using Prism version 5 (GraphPad 
Software).
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